GAITHERSBURG, Md., March 11, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX) today announced it will report its fourth quarter 2018 financial and operating results prior to U.S. financial markets opening on Monday, March 18, 2019.
Conference call details are as follows:
|Date:||March 18, 2019|
|Time:||4:30 p.m. U.S. Eastern Time (ET)|
|Dial-in number:||(877) 212-6076 (Domestic) or (707) 287-9331 (International)|
|Webcast:||www.novavax.com, “Investors”/ “Events”|
Conference call and webcast replay:
|Dates:||Starting at 7:30 p.m. ET, March 18, 2019 until|
|7:30 p.m. ET March 25, 2019|
|Dial-in number:||(855) 859-2056 (Domestic) or (404) 537-3406 (International)|
|Webcast:||www.novavax.com, “Investors”/ “Events”, until June 18, 2019|
Novavax, Inc. (NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.
Senior Manager, Investor & Public Relations